Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Authors Buhl R, Banerji D
Received 17 January 2014
Accepted for publication 17 January 2014
Published 19 March 2014 Volume 2014:9(1) Pages 287—288
Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741.
On page 737 in the first paragraph of the "Safety" section, the final sentence "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (13%) and the tiotropium group (15%, Table 3).32,33" should read "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (10%) compared with placebo (13%) and the tiotropium group (15%, Table 3).32,33"
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]